 Lisa Bero
Concepts (718)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Conflict of Interest | 86 | 2025 | 130 | 22.090 |
Why?
| | Drug Industry | 63 | 2025 | 111 | 16.460 |
Why?
| | Research Support as Topic | 40 | 2024 | 119 | 8.800 |
Why?
| | Tobacco Industry | 35 | 2018 | 62 | 7.600 |
Why?
| | Industry | 27 | 2024 | 68 | 5.990 |
Why?
| | Publication Bias | 25 | 2024 | 41 | 5.830 |
Why?
| | Research Design | 40 | 2025 | 1139 | 5.810 |
Why?
| | Publishing | 36 | 2024 | 147 | 5.670 |
Why?
| | Disclosure | 30 | 2025 | 113 | 5.460 |
Why?
| | Review Literature as Topic | 24 | 2023 | 75 | 5.110 |
Why?
| | Health Policy | 24 | 2022 | 388 | 4.720 |
Why?
| | Biomedical Research | 26 | 2025 | 692 | 4.670 |
Why?
| | Evidence-Based Medicine | 29 | 2024 | 740 | 4.600 |
Why?
| | Public Health | 31 | 2025 | 588 | 4.540 |
Why?
| | World Health Organization | 23 | 2022 | 123 | 4.400 |
Why?
| | Policy Making | 21 | 2022 | 98 | 4.260 |
Why?
| | Practice Guidelines as Topic | 22 | 2021 | 1587 | 3.640 |
Why?
| | Meta-Analysis as Topic | 18 | 2024 | 186 | 3.500 |
Why?
| | Bias | 21 | 2024 | 218 | 3.370 |
Why?
| | Randomized Controlled Trials as Topic | 27 | 2025 | 1477 | 3.360 |
Why?
| | Scientific Misconduct | 6 | 2024 | 12 | 3.070 |
Why?
| | Pharmaceutical Preparations | 10 | 2022 | 179 | 2.930 |
Why?
| | Editorial Policies | 11 | 2025 | 52 | 2.790 |
Why?
| | Mobile Applications | 8 | 2020 | 183 | 2.740 |
Why?
| | Australia | 25 | 2023 | 315 | 2.680 |
Why?
| | Nutritional Sciences | 7 | 2024 | 44 | 2.560 |
Why?
| | Periodicals as Topic | 20 | 2025 | 211 | 2.550 |
Why?
| | Smoking | 27 | 2016 | 1627 | 2.500 |
Why?
| | Humans | 281 | 2025 | 137585 | 2.310 |
Why?
| | Smoking Prevention | 13 | 2012 | 184 | 2.290 |
Why?
| | Food Industry | 8 | 2024 | 16 | 2.250 |
Why?
| | Environmental Exposure | 7 | 2025 | 579 | 2.180 |
Why?
| | Health Personnel | 11 | 2024 | 710 | 2.140 |
Why?
| | Environmental Health | 8 | 2025 | 48 | 2.110 |
Why?
| | Nutrition Policy | 5 | 2020 | 61 | 2.070 |
Why?
| | Observational Studies as Topic | 6 | 2024 | 117 | 2.010 |
Why?
| | Clinical Trials as Topic | 18 | 2021 | 1050 | 1.990 |
Why?
| | Marketing | 10 | 2024 | 30 | 1.980 |
Why?
| | Equipment and Supplies | 8 | 2020 | 42 | 1.960 |
Why?
| | Research Report | 5 | 2019 | 83 | 1.950 |
Why?
| | Information Dissemination | 10 | 2021 | 218 | 1.840 |
Why?
| | Peer Review, Research | 12 | 2025 | 43 | 1.820 |
Why?
| | United States Food and Drug Administration | 14 | 2015 | 208 | 1.760 |
Why?
| | Guideline Adherence | 8 | 2019 | 556 | 1.750 |
Why?
| | Tobacco Smoke Pollution | 17 | 2006 | 261 | 1.710 |
Why?
| | Qualitative Research | 14 | 2025 | 1386 | 1.640 |
Why?
| | Hydroxymethylglutaryl-CoA Reductase Inhibitors | 5 | 2018 | 445 | 1.600 |
Why?
| | Ethics, Research | 5 | 2020 | 33 | 1.590 |
Why?
| | Government Regulation | 13 | 2019 | 54 | 1.550 |
Why?
| | Environmental Pollutants | 6 | 2018 | 159 | 1.520 |
Why?
| | Drugs, Essential | 5 | 2018 | 8 | 1.480 |
Why?
| | Propaganda | 3 | 2019 | 3 | 1.470 |
Why?
| | Research | 19 | 2020 | 451 | 1.470 |
Why?
| | Public Policy | 7 | 2016 | 85 | 1.440 |
Why?
| | Authorship | 11 | 2024 | 53 | 1.410 |
Why?
| | Research Personnel | 6 | 2024 | 173 | 1.400 |
Why?
| | United States | 69 | 2025 | 14841 | 1.380 |
Why?
| | Politics | 9 | 2020 | 98 | 1.370 |
Why?
| | Cross-Sectional Studies | 31 | 2025 | 5472 | 1.330 |
Why?
| | Bibliometrics | 6 | 2018 | 63 | 1.300 |
Why?
| | Data Collection | 9 | 2019 | 673 | 1.300 |
Why?
| | Air Pollution, Indoor | 4 | 2025 | 180 | 1.270 |
Why?
| | Coronavirus Infections | 4 | 2021 | 364 | 1.190 |
Why?
| | Guidelines as Topic | 7 | 2020 | 275 | 1.180 |
Why?
| | Evidence-Based Practice | 4 | 2020 | 229 | 1.180 |
Why?
| | Physicians | 12 | 2023 | 910 | 1.180 |
Why?
| | Nutritional Status | 5 | 2020 | 350 | 1.170 |
Why?
| | Delivery of Health Care | 5 | 2024 | 951 | 1.130 |
Why?
| | Occupational Health | 6 | 2019 | 200 | 1.120 |
Why?
| | Pharmacy and Therapeutics Committee | 2 | 2020 | 2 | 1.110 |
Why?
| | Commerce | 8 | 2020 | 82 | 1.080 |
Why?
| | Policy | 4 | 2022 | 150 | 1.070 |
Why?
| | Community Pharmacy Services | 2 | 2022 | 45 | 1.060 |
Why?
| | Vitamin D | 2 | 2021 | 397 | 1.060 |
Why?
| | Risk Management | 2 | 2022 | 93 | 1.030 |
Why?
| | Advanced Practice Nursing | 2 | 2025 | 39 | 1.020 |
Why?
| | Interprofessional Relations | 5 | 2021 | 283 | 1.010 |
Why?
| | Health Promotion | 8 | 2019 | 741 | 1.000 |
Why?
| | Drug Approval | 5 | 2015 | 88 | 0.990 |
Why?
| | Diet | 6 | 2024 | 1278 | 0.990 |
Why?
| | Education, Medical, Continuing | 4 | 2019 | 127 | 0.990 |
Why?
| | Workplace | 5 | 2009 | 261 | 0.990 |
Why?
| | Decision Making | 11 | 2025 | 900 | 0.980 |
Why?
| | Bone and Bones | 2 | 2021 | 317 | 0.960 |
Why?
| | Cardiovascular Diseases | 7 | 2021 | 2111 | 0.950 |
Why?
| | Deprescriptions | 5 | 2023 | 35 | 0.930 |
Why?
| | Lobbying | 6 | 2006 | 8 | 0.930 |
Why?
| | Interrupted Time Series Analysis | 7 | 2022 | 68 | 0.910 |
Why?
| | Practice Patterns, Physicians' | 12 | 2021 | 1313 | 0.890 |
Why?
| | Medical Overuse | 4 | 2019 | 30 | 0.870 |
Why?
| | Financial Support | 5 | 2019 | 22 | 0.870 |
Why?
| | Toxicity Tests | 3 | 2016 | 37 | 0.870 |
Why?
| | Spinal Cord Stimulation | 1 | 2024 | 8 | 0.860 |
Why?
| | Risk Assessment | 10 | 2022 | 3457 | 0.850 |
Why?
| | Infection Control | 1 | 2025 | 167 | 0.850 |
Why?
| | Consumer Advocacy | 2 | 2020 | 12 | 0.830 |
Why?
| | Formularies as Topic | 3 | 2018 | 6 | 0.820 |
Why?
| | Codeine | 1 | 2022 | 6 | 0.810 |
Why?
| | Pandemics | 7 | 2023 | 1639 | 0.800 |
Why?
| | Telemedicine | 4 | 2019 | 862 | 0.780 |
Why?
| | Health Education | 2 | 2018 | 341 | 0.770 |
Why?
| | Tobacco Products | 5 | 2018 | 138 | 0.760 |
Why?
| | Drug Evaluation | 5 | 2012 | 84 | 0.760 |
Why?
| | Epidemiologic Methods | 2 | 2022 | 97 | 0.760 |
Why?
| | Health Priorities | 2 | 2012 | 44 | 0.750 |
Why?
| | Nursing Care | 1 | 2022 | 43 | 0.750 |
Why?
| | Dietary Supplements | 2 | 2021 | 561 | 0.750 |
Why?
| | Confidentiality | 2 | 2021 | 73 | 0.740 |
Why?
| | Retraction of Publication as Topic | 1 | 2021 | 1 | 0.730 |
Why?
| | Recommended Dietary Allowances | 1 | 2021 | 18 | 0.720 |
Why?
| | Group Practice | 1 | 2021 | 7 | 0.710 |
Why?
| | Respiratory Tract Infections | 1 | 2025 | 390 | 0.700 |
Why?
| | Advisory Committees | 6 | 2020 | 219 | 0.690 |
Why?
| | Attitude | 4 | 2013 | 259 | 0.690 |
Why?
| | Bone Remodeling | 1 | 2021 | 75 | 0.690 |
Why?
| | Technology Transfer | 2 | 2019 | 9 | 0.690 |
Why?
| | Contact Tracing | 1 | 2020 | 27 | 0.680 |
Why?
| | Gift Giving | 2 | 2019 | 11 | 0.670 |
Why?
| | Betacoronavirus | 2 | 2020 | 270 | 0.670 |
Why?
| | Selection Bias | 3 | 2024 | 37 | 0.670 |
Why?
| | Checklist | 1 | 2021 | 93 | 0.670 |
Why?
| | Calcium | 2 | 2021 | 1199 | 0.660 |
Why?
| | Interviews as Topic | 7 | 2019 | 786 | 0.660 |
Why?
| | Societies, Scientific | 1 | 2020 | 51 | 0.660 |
Why?
| | Societies | 1 | 2020 | 39 | 0.660 |
Why?
| | Atherosclerosis | 2 | 2015 | 415 | 0.660 |
Why?
| | Cannabis | 2 | 2025 | 494 | 0.650 |
Why?
| | Beverages | 2 | 2019 | 69 | 0.650 |
Why?
| | Organizational Policy | 7 | 2011 | 84 | 0.650 |
Why?
| | Science | 3 | 2007 | 53 | 0.650 |
Why?
| | Public Opinion | 7 | 2015 | 65 | 0.650 |
Why?
| | Pharmacists | 8 | 2022 | 265 | 0.640 |
Why?
| | Attitude to Health | 6 | 2015 | 439 | 0.640 |
Why?
| | Dental Research | 1 | 2019 | 5 | 0.640 |
Why?
| | Marketing of Health Services | 3 | 2018 | 14 | 0.630 |
Why?
| | Calcium, Dietary | 1 | 2019 | 57 | 0.630 |
Why?
| | Off-Label Use | 3 | 2015 | 52 | 0.630 |
Why?
| | Whole Grains | 1 | 2019 | 3 | 0.630 |
Why?
| | Patient Advocacy | 2 | 2019 | 76 | 0.620 |
Why?
| | Gynecology | 1 | 2021 | 168 | 0.610 |
Why?
| | Hazardous Substances | 2 | 2018 | 18 | 0.600 |
Why?
| | Tobacco Use Disorder | 4 | 2010 | 251 | 0.600 |
Why?
| | Databases, Factual | 5 | 2020 | 1357 | 0.600 |
Why?
| | International Cooperation | 7 | 2011 | 198 | 0.590 |
Why?
| | Journalism | 2 | 2012 | 7 | 0.590 |
Why?
| | Internet | 4 | 2019 | 655 | 0.590 |
Why?
| | Professional Role | 4 | 2022 | 167 | 0.580 |
Why?
| | Dronabinol | 3 | 2025 | 226 | 0.580 |
Why?
| | Health Behavior | 4 | 2021 | 762 | 0.580 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 373 | 0.580 |
Why?
| | Vitamins | 1 | 2019 | 185 | 0.580 |
Why?
| | Quality Control | 8 | 2013 | 172 | 0.570 |
Why?
| | Food Analysis | 1 | 2018 | 26 | 0.570 |
Why?
| | Fluorocarbons | 2 | 2023 | 117 | 0.570 |
Why?
| | Nicotine | 8 | 2006 | 334 | 0.570 |
Why?
| | Pharmaceutical Services | 3 | 2013 | 83 | 0.570 |
Why?
| | Access to Information | 3 | 2014 | 49 | 0.570 |
Why?
| | Analgesics, Opioid | 7 | 2023 | 1000 | 0.570 |
Why?
| | Writing | 2 | 2019 | 95 | 0.570 |
Why?
| | Health Services | 3 | 2013 | 107 | 0.570 |
Why?
| | Developing Countries | 4 | 2018 | 307 | 0.570 |
Why?
| | Cooperative Behavior | 3 | 2013 | 451 | 0.560 |
Why?
| | Databases, Bibliographic | 3 | 2014 | 32 | 0.560 |
Why?
| | Capital Financing | 1 | 2017 | 8 | 0.560 |
Why?
| | Population Health | 1 | 2018 | 47 | 0.540 |
Why?
| | Disease Outbreaks | 1 | 2020 | 395 | 0.530 |
Why?
| | Interinstitutional Relations | 5 | 2013 | 53 | 0.530 |
Why?
| | Nurses | 2 | 2016 | 180 | 0.530 |
Why?
| | Peer Review | 5 | 2015 | 49 | 0.520 |
Why?
| | Vaccines | 1 | 2022 | 406 | 0.520 |
Why?
| | Drug Evaluation, Preclinical | 2 | 2015 | 184 | 0.520 |
Why?
| | Government Agencies | 2 | 2015 | 17 | 0.520 |
Why?
| | Obesity | 4 | 2023 | 2992 | 0.510 |
Why?
| | Primary Prevention | 1 | 2018 | 196 | 0.510 |
Why?
| | Models, Organizational | 3 | 2008 | 151 | 0.510 |
Why?
| | Tobacco Use Cessation | 1 | 2016 | 27 | 0.510 |
Why?
| | Opioid-Related Disorders | 2 | 2023 | 515 | 0.500 |
Why?
| | Drug Prescriptions | 4 | 2022 | 245 | 0.500 |
Why?
| | Sweetening Agents | 1 | 2016 | 54 | 0.500 |
Why?
| | Atrazine | 1 | 2015 | 8 | 0.490 |
Why?
| | Libraries, Digital | 2 | 2012 | 4 | 0.490 |
Why?
| | California | 9 | 2013 | 431 | 0.490 |
Why?
| | Medication Adherence | 1 | 2019 | 467 | 0.490 |
Why?
| | Drug Overdose | 1 | 2020 | 347 | 0.480 |
Why?
| | Pharmacies | 1 | 2015 | 38 | 0.470 |
Why?
| | Medicaid | 4 | 2013 | 435 | 0.470 |
Why?
| | Databases, Pharmaceutical | 1 | 2015 | 5 | 0.470 |
Why?
| | Patient Care Planning | 1 | 2016 | 157 | 0.470 |
Why?
| | Fees, Pharmaceutical | 2 | 2014 | 9 | 0.470 |
Why?
| | Epidemiologic Studies | 2 | 2022 | 72 | 0.460 |
Why?
| | Information Services | 4 | 2002 | 49 | 0.460 |
Why?
| | Fetal Development | 2 | 2016 | 296 | 0.460 |
Why?
| | Cohort Studies | 7 | 2022 | 5742 | 0.450 |
Why?
| | Academic Medical Centers | 4 | 2018 | 512 | 0.450 |
Why?
| | Caprylates | 1 | 2014 | 25 | 0.450 |
Why?
| | Knowledge | 2 | 2012 | 55 | 0.450 |
Why?
| | Anticoagulants | 1 | 2019 | 664 | 0.450 |
Why?
| | Canada | 7 | 2022 | 418 | 0.440 |
Why?
| | Expert Testimony | 3 | 2020 | 39 | 0.440 |
Why?
| | Teaching Materials | 2 | 2007 | 23 | 0.440 |
Why?
| | Quality of Health Care | 4 | 2012 | 642 | 0.440 |
Why?
| | Treatment Outcome | 16 | 2018 | 10811 | 0.430 |
Why?
| | Universities | 4 | 2007 | 433 | 0.420 |
Why?
| | Mass Media | 5 | 2001 | 42 | 0.410 |
Why?
| | Occupational Exposure | 3 | 2022 | 341 | 0.410 |
Why?
| | Cyclohexanecarboxylic Acids | 3 | 2009 | 22 | 0.410 |
Why?
| | Counseling | 1 | 2016 | 391 | 0.410 |
Why?
| | Amines | 3 | 2009 | 40 | 0.410 |
Why?
| | Social Support | 1 | 2017 | 618 | 0.410 |
Why?
| | Community Participation | 2 | 2010 | 131 | 0.410 |
Why?
| | Depressive Disorder, Major | 1 | 2017 | 364 | 0.410 |
Why?
| | Financial Management | 3 | 2012 | 18 | 0.400 |
Why?
| | Ambulatory Care | 3 | 2010 | 546 | 0.400 |
Why?
| | Angiogenesis Inhibitors | 1 | 2014 | 229 | 0.390 |
Why?
| | Documentation | 5 | 2018 | 194 | 0.390 |
Why?
| | Macular Degeneration | 1 | 2014 | 164 | 0.390 |
Why?
| | Substance-Related Disorders | 7 | 2016 | 1083 | 0.390 |
Why?
| | Carcinogens | 2 | 2020 | 125 | 0.390 |
Why?
| | Infant Formula | 2 | 2024 | 75 | 0.380 |
Why?
| | Cholesterol, LDL | 1 | 2014 | 365 | 0.380 |
Why?
| | Thinking | 1 | 2013 | 65 | 0.380 |
Why?
| | Device Approval | 4 | 2015 | 21 | 0.380 |
Why?
| | Medication Therapy Management | 1 | 2013 | 76 | 0.380 |
Why?
| | Body Weight | 1 | 2016 | 985 | 0.380 |
Why?
| | Overweight | 1 | 2016 | 558 | 0.370 |
Why?
| | Federal Government | 3 | 2009 | 28 | 0.370 |
Why?
| | Human Experimentation | 2 | 2009 | 13 | 0.360 |
Why?
| | gamma-Aminobutyric Acid | 3 | 2009 | 198 | 0.360 |
Why?
| | Attitude of Health Personnel | 7 | 2023 | 1171 | 0.360 |
Why?
| | Publications | 3 | 2020 | 47 | 0.360 |
Why?
| | Global Health | 3 | 2020 | 386 | 0.350 |
Why?
| | Birth Weight | 1 | 2014 | 516 | 0.350 |
Why?
| | Oncologists | 2 | 2021 | 38 | 0.350 |
Why?
| | Organizations, Nonprofit | 1 | 2011 | 17 | 0.350 |
Why?
| | Prejudice | 3 | 2017 | 73 | 0.340 |
Why?
| | Health Services Accessibility | 4 | 2015 | 986 | 0.340 |
Why?
| | Health Knowledge, Attitudes, Practice | 6 | 2021 | 1329 | 0.340 |
Why?
| | Relief Work | 1 | 2010 | 19 | 0.340 |
Why?
| | Mental Health | 3 | 2025 | 726 | 0.340 |
Why?
| | Decision Making, Organizational | 2 | 2007 | 29 | 0.340 |
Why?
| | Thrombosis | 1 | 2014 | 371 | 0.340 |
Why?
| | Neoplasms | 9 | 2023 | 2671 | 0.340 |
Why?
| | Teaching | 1 | 2013 | 224 | 0.340 |
Why?
| | Patient Education as Topic | 2 | 2013 | 766 | 0.340 |
Why?
| | Decision Support Techniques | 1 | 2014 | 421 | 0.330 |
Why?
| | Public Relations | 5 | 2017 | 6 | 0.330 |
Why?
| | Trust | 3 | 2025 | 127 | 0.330 |
Why?
| | Child Welfare | 1 | 2012 | 216 | 0.330 |
Why?
| | Drug-Related Side Effects and Adverse Reactions | 5 | 2014 | 250 | 0.330 |
Why?
| | Drug Labeling | 2 | 2013 | 39 | 0.330 |
Why?
| | Congresses as Topic | 4 | 1997 | 233 | 0.320 |
Why?
| | Cluster Analysis | 1 | 2011 | 499 | 0.320 |
Why?
| | Prescription Drugs | 4 | 2017 | 109 | 0.320 |
Why?
| | Health Care Sector | 2 | 2020 | 25 | 0.320 |
Why?
| | Patient Satisfaction | 4 | 2017 | 660 | 0.320 |
Why?
| | Women's Health | 1 | 2012 | 372 | 0.310 |
Why?
| | Economic Development | 1 | 2009 | 3 | 0.310 |
Why?
| | Ethics, Institutional | 1 | 2009 | 5 | 0.310 |
Why?
| | Social Control Policies | 1 | 2008 | 1 | 0.310 |
Why?
| | Health Care Costs | 4 | 2019 | 398 | 0.310 |
Why?
| | Ethics, Professional | 1 | 2009 | 14 | 0.310 |
Why?
| | Occupational Diseases | 2 | 2022 | 156 | 0.300 |
Why?
| | Antibodies, Monoclonal, Humanized | 1 | 2014 | 804 | 0.300 |
Why?
| | Restaurants | 1 | 2008 | 25 | 0.300 |
Why?
| | Poverty | 2 | 2010 | 521 | 0.300 |
Why?
| | Law Enforcement | 1 | 2008 | 39 | 0.300 |
Why?
| | Life Style | 2 | 2021 | 490 | 0.300 |
Why?
| | Thiazolidinediones | 1 | 2009 | 137 | 0.290 |
Why?
| | Laboratories | 1 | 2009 | 113 | 0.280 |
Why?
| | Morals | 1 | 2009 | 82 | 0.280 |
Why?
| | Ethics Committees, Research | 1 | 2007 | 42 | 0.280 |
Why?
| | Research Subjects | 1 | 2007 | 42 | 0.270 |
Why?
| | Uncertainty | 2 | 2021 | 128 | 0.270 |
Why?
| | Drug and Narcotic Control | 3 | 2021 | 28 | 0.270 |
Why?
| | Consumer Organizations | 1 | 2007 | 1 | 0.270 |
Why?
| | Privacy | 3 | 2020 | 42 | 0.270 |
Why?
| | Plants, Toxic | 6 | 1995 | 24 | 0.270 |
Why?
| | Osteoporosis | 3 | 2021 | 243 | 0.270 |
Why?
| | Nutritional Physiological Phenomena | 2 | 2017 | 54 | 0.270 |
Why?
| | Deception | 1 | 2007 | 20 | 0.270 |
Why?
| | Minority Groups | 1 | 2009 | 266 | 0.260 |
Why?
| | Smoking Cessation | 5 | 2018 | 442 | 0.260 |
Why?
| | Europe | 4 | 2021 | 414 | 0.260 |
Why?
| | Books | 1 | 2006 | 3 | 0.260 |
Why?
| | Aircraft | 1 | 2006 | 22 | 0.260 |
Why?
| | Aerospace Medicine | 1 | 2006 | 29 | 0.250 |
Why?
| | Female | 26 | 2025 | 73304 | 0.250 |
Why?
| | United States Dept. of Health and Human Services | 1 | 2006 | 2 | 0.250 |
Why?
| | Schizophrenia | 2 | 2025 | 439 | 0.250 |
Why?
| | Nonprescription Drugs | 1 | 2006 | 63 | 0.240 |
Why?
| | Health Status Disparities | 1 | 2009 | 289 | 0.240 |
Why?
| | Adolescent Behavior | 2 | 2002 | 530 | 0.240 |
Why?
| | Consumer Product Safety | 3 | 2019 | 33 | 0.240 |
Why?
| | Animals | 21 | 2024 | 36940 | 0.240 |
Why?
| | Disease | 2 | 2019 | 98 | 0.240 |
Why?
| | MEDLINE | 3 | 2014 | 21 | 0.240 |
Why?
| | Insurance Claim Reporting | 1 | 2005 | 24 | 0.240 |
Why?
| | Drug Utilization | 3 | 2022 | 169 | 0.230 |
Why?
| | Air Microbiology | 1 | 2025 | 47 | 0.230 |
Why?
| | Bone Density | 1 | 2009 | 489 | 0.230 |
Why?
| | Data Interpretation, Statistical | 3 | 2017 | 363 | 0.230 |
Why?
| | Animal Experimentation | 1 | 2024 | 6 | 0.230 |
Why?
| | Pharmacy Service, Hospital | 3 | 2002 | 90 | 0.230 |
Why?
| | Animals, Laboratory | 1 | 2024 | 18 | 0.220 |
Why?
| | Harm Reduction | 1 | 2004 | 39 | 0.220 |
Why?
| | International Classification of Diseases | 1 | 2005 | 135 | 0.220 |
Why?
| | Education | 1 | 2025 | 108 | 0.220 |
Why?
| | Adult | 12 | 2025 | 37929 | 0.220 |
Why?
| | Health Care Surveys | 3 | 2013 | 565 | 0.210 |
Why?
| | Evaluation Studies as Topic | 3 | 2019 | 180 | 0.210 |
Why?
| | Case-Control Studies | 2 | 2024 | 3556 | 0.210 |
Why?
| | Cost-Benefit Analysis | 4 | 2015 | 591 | 0.210 |
Why?
| | Consultants | 2 | 2020 | 13 | 0.210 |
Why?
| | Receptors, Opioid | 3 | 1988 | 25 | 0.210 |
Why?
| | Primary Health Care | 3 | 2020 | 1738 | 0.210 |
Why?
| | Antihypertensive Agents | 1 | 2007 | 494 | 0.210 |
Why?
| | Depression | 2 | 2003 | 1397 | 0.210 |
Why?
| | Data Accuracy | 2 | 2021 | 65 | 0.210 |
Why?
| | Quarantine | 2 | 2020 | 30 | 0.210 |
Why?
| | Mental Disorders | 2 | 2025 | 1077 | 0.210 |
Why?
| | Data Mining | 2 | 2015 | 116 | 0.210 |
Why?
| | Medical Marijuana | 1 | 2025 | 117 | 0.210 |
Why?
| | Sample Size | 2 | 2014 | 125 | 0.200 |
Why?
| | Journal Impact Factor | 3 | 2020 | 28 | 0.200 |
Why?
| | Prolactin | 4 | 1987 | 96 | 0.200 |
Why?
| | Male | 21 | 2023 | 67762 | 0.200 |
Why?
| | Public Health Practice | 2 | 2010 | 70 | 0.200 |
Why?
| | State Government | 3 | 2009 | 42 | 0.200 |
Why?
| | Private Sector | 2 | 2000 | 52 | 0.200 |
Why?
| | Estonia | 2 | 2012 | 2 | 0.200 |
Why?
| | Drug Therapy | 5 | 2011 | 85 | 0.200 |
Why?
| | Datasets as Topic | 2 | 2020 | 121 | 0.200 |
Why?
| | Nurse Practitioners | 1 | 2025 | 138 | 0.190 |
Why?
| | Fraud | 1 | 2022 | 9 | 0.190 |
Why?
| | Health Status | 2 | 2021 | 792 | 0.190 |
Why?
| | Risk | 2 | 2016 | 912 | 0.190 |
Why?
| | Program Development | 2 | 2016 | 364 | 0.190 |
Why?
| | Food | 2 | 2024 | 164 | 0.190 |
Why?
| | Torsades de Pointes | 1 | 2022 | 24 | 0.190 |
Why?
| | Libraries, Medical | 1 | 2002 | 11 | 0.190 |
Why?
| | Newspapers as Topic | 2 | 2001 | 10 | 0.190 |
Why?
| | Truth Disclosure | 7 | 2011 | 48 | 0.190 |
Why?
| | Chemical Industry | 2 | 2013 | 12 | 0.180 |
Why?
| | Analgesics | 1 | 2023 | 206 | 0.180 |
Why?
| | Alcohol Drinking | 1 | 2008 | 828 | 0.180 |
Why?
| | Program Evaluation | 4 | 2020 | 898 | 0.180 |
Why?
| | History, 21st Century | 2 | 2018 | 213 | 0.180 |
Why?
| | Risk Factors | 7 | 2022 | 10388 | 0.180 |
Why?
| | Child | 9 | 2020 | 21935 | 0.180 |
Why?
| | Facility Regulation and Control | 1 | 2000 | 4 | 0.180 |
Why?
| | Long QT Syndrome | 1 | 2022 | 70 | 0.170 |
Why?
| | Sodium, Dietary | 1 | 2021 | 41 | 0.170 |
Why?
| | Double-Blind Method | 2 | 2018 | 1993 | 0.170 |
Why?
| | Sierra Leone | 1 | 2020 | 2 | 0.170 |
Why?
| | Administrative Personnel | 1 | 2020 | 29 | 0.170 |
Why?
| | Botswana | 1 | 2020 | 9 | 0.170 |
Why?
| | Medical Oncology | 1 | 2023 | 289 | 0.170 |
Why?
| | United States Agency for Healthcare Research and Quality | 1 | 2020 | 10 | 0.170 |
Why?
| | Patient Isolation | 1 | 2020 | 19 | 0.170 |
Why?
| | Antidepressive Agents | 1 | 2002 | 236 | 0.170 |
Why?
| | Antineoplastic Agents | 2 | 2009 | 2129 | 0.170 |
Why?
| | Thiadiazines | 1 | 2020 | 2 | 0.170 |
Why?
| | Whooping Cough | 1 | 2020 | 51 | 0.170 |
Why?
| | Healthcare Disparities | 2 | 2021 | 654 | 0.170 |
Why?
| | Codes of Ethics | 2 | 2018 | 19 | 0.170 |
Why?
| | Hemorrhagic Fever, Ebola | 1 | 2020 | 36 | 0.170 |
Why?
| | Organizational Case Studies | 3 | 2010 | 78 | 0.170 |
Why?
| | Artificial Intelligence | 1 | 2023 | 279 | 0.170 |
Why?
| | Faculty, Medical | 2 | 2000 | 283 | 0.160 |
Why?
| | Psychology, Adolescent | 1 | 2000 | 66 | 0.160 |
Why?
| | Reproduction | 1 | 2021 | 204 | 0.160 |
Why?
| | Food Safety | 1 | 2020 | 22 | 0.160 |
Why?
| | Postpartum Hemorrhage | 1 | 2019 | 17 | 0.160 |
Why?
| | Medicare | 1 | 2005 | 773 | 0.160 |
Why?
| | Dabigatran | 1 | 2019 | 22 | 0.160 |
Why?
| | Social Control, Formal | 1 | 2019 | 12 | 0.150 |
Why?
| | Nutritive Value | 1 | 2019 | 37 | 0.150 |
Why?
| | Surveys and Questionnaires | 8 | 2024 | 5778 | 0.150 |
Why?
| | Organizational Affiliation | 2 | 2000 | 8 | 0.150 |
Why?
| | Models, Theoretical | 2 | 2020 | 578 | 0.150 |
Why?
| | Secondary Prevention | 1 | 2020 | 233 | 0.150 |
Why?
| | Computer Security | 1 | 2019 | 23 | 0.150 |
Why?
| | Food Supply | 1 | 2020 | 83 | 0.150 |
Why?
| | Chronic Pain | 1 | 2023 | 262 | 0.150 |
Why?
| | Stakeholder Participation | 1 | 2019 | 78 | 0.150 |
Why?
| | Middle Aged | 7 | 2023 | 33479 | 0.150 |
Why?
| | Random Allocation | 2 | 2024 | 353 | 0.150 |
Why?
| | Oral Health | 1 | 2020 | 124 | 0.150 |
Why?
| | Health Risk Behaviors | 1 | 2018 | 16 | 0.150 |
Why?
| | Schools | 1 | 2002 | 461 | 0.150 |
Why?
| | Intersectoral Collaboration | 1 | 2018 | 60 | 0.140 |
Why?
| | Information Storage and Retrieval | 2 | 2015 | 118 | 0.140 |
Why?
| | Professional Practice | 1 | 1998 | 64 | 0.140 |
Why?
| | Practice Management, Medical | 1 | 2018 | 35 | 0.140 |
Why?
| | Retrospective Studies | 5 | 2022 | 15657 | 0.140 |
Why?
| | Eating | 1 | 2020 | 380 | 0.140 |
Why?
| | Morphine | 4 | 1987 | 158 | 0.140 |
Why?
| | Statistics as Topic | 1 | 2019 | 307 | 0.140 |
Why?
| | Pyridones | 1 | 2019 | 168 | 0.140 |
Why?
| | Urinary Bladder, Overactive | 1 | 2018 | 22 | 0.140 |
Why?
| | Costs and Cost Analysis | 2 | 2022 | 213 | 0.140 |
Why?
| | United Kingdom | 3 | 2022 | 318 | 0.140 |
Why?
| | Rivaroxaban | 1 | 2019 | 255 | 0.130 |
Why?
| | Tuberculosis | 1 | 2020 | 279 | 0.130 |
Why?
| | Health Resources | 1 | 2018 | 120 | 0.130 |
Why?
| | Informed Consent | 2 | 2024 | 175 | 0.130 |
Why?
| | Linear Models | 2 | 2020 | 849 | 0.130 |
Why?
| | Food Handling | 1 | 2016 | 61 | 0.130 |
Why?
| | Quality of Life | 3 | 2023 | 2892 | 0.130 |
Why?
| | Patient Participation | 2 | 1997 | 420 | 0.130 |
Why?
| | Triclosan | 1 | 2016 | 10 | 0.130 |
Why?
| | Brain Chemistry | 2 | 1988 | 117 | 0.130 |
Why?
| | Statistics, Nonparametric | 2 | 2012 | 431 | 0.130 |
Why?
| | Nutrition Assessment | 1 | 2016 | 92 | 0.130 |
Why?
| | Patient Selection | 2 | 2011 | 696 | 0.130 |
Why?
| | Judgment | 1 | 2016 | 60 | 0.130 |
Why?
| | Information Centers | 1 | 1995 | 4 | 0.120 |
Why?
| | Endocrine Disruptors | 1 | 2016 | 42 | 0.120 |
Why?
| | Epidemiologic Research Design | 1 | 2016 | 29 | 0.120 |
Why?
| | Thyroxine | 1 | 2016 | 62 | 0.120 |
Why?
| | Environmental Monitoring | 1 | 2018 | 370 | 0.120 |
Why?
| | 5-Hydroxytryptophan | 2 | 1987 | 21 | 0.120 |
Why?
| | Pyrazoles | 1 | 2019 | 423 | 0.120 |
Why?
| | Leadership | 1 | 2020 | 388 | 0.120 |
Why?
| | Pregnancy | 6 | 2019 | 6763 | 0.120 |
Why?
| | Malnutrition | 1 | 2016 | 83 | 0.120 |
Why?
| | Venous Thromboembolism | 1 | 2019 | 316 | 0.120 |
Why?
| | Health | 1 | 2015 | 84 | 0.120 |
Why?
| | Calcium Channel Blockers | 1 | 1996 | 167 | 0.110 |
Why?
| | Sex Factors | 2 | 2012 | 2071 | 0.110 |
Why?
| | Ranibizumab | 1 | 2014 | 20 | 0.110 |
Why?
| | Infant, Newborn | 2 | 2020 | 6079 | 0.110 |
Why?
| | Medical Informatics | 1 | 2015 | 101 | 0.110 |
Why?
| | Depressive Disorder | 1 | 2018 | 379 | 0.110 |
Why?
| | Italy | 1 | 2014 | 110 | 0.110 |
Why?
| | Legislation, Food | 1 | 2013 | 2 | 0.110 |
Why?
| | Hypertension | 2 | 2010 | 1295 | 0.110 |
Why?
| | Adverse Drug Reaction Reporting Systems | 2 | 2011 | 77 | 0.110 |
Why?
| | Food Additives | 1 | 2013 | 7 | 0.110 |
Why?
| | Equipment Safety | 2 | 2010 | 37 | 0.110 |
Why?
| | Bevacizumab | 1 | 2014 | 138 | 0.110 |
Why?
| | Reproducibility of Results | 6 | 2024 | 3284 | 0.110 |
Why?
| | Nursing Staff, Hospital | 1 | 2016 | 162 | 0.110 |
Why?
| | History, 20th Century | 2 | 2007 | 325 | 0.100 |
Why?
| | Combined Modality Therapy | 1 | 2016 | 1236 | 0.100 |
Why?
| | Vaccination | 1 | 2022 | 1381 | 0.100 |
Why?
| | Physician's Role | 1 | 2015 | 211 | 0.100 |
Why?
| | Search Engine | 1 | 2013 | 12 | 0.100 |
Why?
| | Health Services Research | 1 | 1996 | 404 | 0.100 |
Why?
| | Lung Neoplasms | 2 | 2005 | 2526 | 0.100 |
Why?
| | Antipsychotic Agents | 1 | 2015 | 194 | 0.100 |
Why?
| | Nursing Homes | 1 | 2015 | 181 | 0.100 |
Why?
| | Clinical Protocols | 2 | 2009 | 271 | 0.100 |
Why?
| | Health Planning Guidelines | 1 | 2012 | 25 | 0.100 |
Why?
| | Wounds and Injuries | 1 | 2019 | 758 | 0.100 |
Why?
| | Total Quality Management | 1 | 2012 | 61 | 0.100 |
Why?
| | Reimbursement Mechanisms | 1 | 2013 | 85 | 0.100 |
Why?
| | Gastroenterology | 1 | 2014 | 180 | 0.090 |
Why?
| | Pain | 3 | 2023 | 756 | 0.090 |
Why?
| | Legislation, Drug | 2 | 2010 | 80 | 0.090 |
Why?
| | Americas | 1 | 2011 | 28 | 0.090 |
Why?
| | Switzerland | 1 | 2011 | 37 | 0.090 |
Why?
| | Maryland | 2 | 2002 | 60 | 0.090 |
Why?
| | Libraries | 1 | 2011 | 4 | 0.090 |
Why?
| | Diabetes Mellitus | 1 | 2020 | 1040 | 0.090 |
Why?
| | Comprehension | 1 | 2013 | 172 | 0.090 |
Why?
| | Cardiac Resynchronization Therapy Devices | 1 | 2011 | 11 | 0.090 |
Why?
| | Eclampsia | 1 | 2010 | 4 | 0.090 |
Why?
| | Health Services Needs and Demand | 1 | 2013 | 273 | 0.090 |
Why?
| | Tocolytic Agents | 1 | 2010 | 16 | 0.090 |
Why?
| | Guatemala | 1 | 2012 | 327 | 0.090 |
Why?
| | Magnesium Sulfate | 1 | 2010 | 17 | 0.090 |
Why?
| | Aged | 7 | 2014 | 23961 | 0.090 |
Why?
| | Self Concept | 1 | 2012 | 253 | 0.090 |
Why?
| | Mammography | 1 | 2012 | 154 | 0.090 |
Why?
| | Quality Assurance, Health Care | 3 | 2012 | 322 | 0.090 |
Why?
| | Education, Pharmacy, Continuing | 1 | 2010 | 3 | 0.080 |
Why?
| | Serotonin | 3 | 1987 | 323 | 0.080 |
Why?
| | Educational Status | 1 | 2012 | 470 | 0.080 |
Why?
| | Time Factors | 1 | 2021 | 6828 | 0.080 |
Why?
| | Prevalence | 3 | 2022 | 2734 | 0.080 |
Why?
| | Health Facilities | 1 | 2010 | 84 | 0.080 |
Why?
| | Age Factors | 2 | 2012 | 3295 | 0.080 |
Why?
| | Rats, Inbred Strains | 5 | 1988 | 362 | 0.080 |
Why?
| | Health Surveys | 1 | 2012 | 514 | 0.080 |
Why?
| | Multicenter Studies as Topic | 1 | 2011 | 310 | 0.080 |
Why?
| | Dose-Response Relationship, Drug | 2 | 2014 | 2057 | 0.080 |
Why?
| | Mandatory Programs | 1 | 2009 | 15 | 0.080 |
Why?
| | Prostheses and Implants | 1 | 2010 | 143 | 0.080 |
Why?
| | Radiology | 1 | 2012 | 180 | 0.080 |
Why?
| | Growth Hormone | 2 | 1987 | 101 | 0.080 |
Why?
| | Vinyl Chloride | 1 | 2009 | 2 | 0.080 |
Why?
| | Disasters | 1 | 2010 | 98 | 0.080 |
Why?
| | Heart-Assist Devices | 1 | 2015 | 552 | 0.080 |
Why?
| | Multivariate Analysis | 2 | 2006 | 1509 | 0.080 |
Why?
| | Breast Feeding | 2 | 2024 | 440 | 0.080 |
Why?
| | Lead Poisoning | 1 | 2009 | 19 | 0.080 |
Why?
| | Placebos | 1 | 2009 | 199 | 0.080 |
Why?
| | Financing, Government | 1 | 2009 | 47 | 0.080 |
Why?
| | Consensus | 2 | 2024 | 683 | 0.070 |
Why?
| | Patient Compliance | 2 | 2003 | 581 | 0.070 |
Why?
| | Learning | 1 | 2012 | 409 | 0.070 |
Why?
| | Silicosis | 1 | 2009 | 27 | 0.070 |
Why?
| | Pre-Eclampsia | 1 | 2010 | 190 | 0.070 |
Why?
| | Rats | 8 | 2016 | 5647 | 0.070 |
Why?
| | Smartphone | 2 | 2019 | 91 | 0.070 |
Why?
| | Methadone | 2 | 1987 | 101 | 0.070 |
Why?
| | Helsinki Declaration | 1 | 2007 | 2 | 0.070 |
Why?
| | Coronary Disease | 1 | 2010 | 385 | 0.070 |
Why?
| | Socioeconomic Factors | 1 | 2012 | 1289 | 0.070 |
Why?
| | Patient Care Team | 2 | 2003 | 631 | 0.070 |
Why?
| | Health Plan Implementation | 1 | 2008 | 142 | 0.070 |
Why?
| | Infant | 3 | 2024 | 9465 | 0.070 |
Why?
| | Motivation | 2 | 2020 | 570 | 0.070 |
Why?
| | Logistic Models | 2 | 2006 | 2074 | 0.070 |
Why?
| | Financing, Organized | 3 | 2003 | 35 | 0.070 |
Why?
| | Propylamines | 1 | 1987 | 10 | 0.070 |
Why?
| | Reference Values | 1 | 2009 | 816 | 0.070 |
Why?
| | Receptors, Dopamine | 1 | 1987 | 20 | 0.070 |
Why?
| | Persuasive Communication | 1 | 2007 | 14 | 0.070 |
Why?
| | Receptors, Serotonin | 1 | 1987 | 34 | 0.070 |
Why?
| | Cardiology | 1 | 2009 | 274 | 0.070 |
Why?
| | Consumer Behavior | 2 | 2004 | 71 | 0.070 |
Why?
| | Longitudinal Studies | 2 | 2022 | 2844 | 0.070 |
Why?
| | Culture | 1 | 2007 | 128 | 0.060 |
Why?
| | Regression Analysis | 1 | 2009 | 1024 | 0.060 |
Why?
| | Fluoxetine | 1 | 1987 | 54 | 0.060 |
Why?
| | Adolescent | 4 | 2010 | 21513 | 0.060 |
Why?
| | Receptors, Adrenergic, alpha | 1 | 1986 | 26 | 0.060 |
Why?
| | Hypothalamus | 1 | 1987 | 153 | 0.060 |
Why?
| | United States Public Health Service | 1 | 2006 | 10 | 0.060 |
Why?
| | Mothers | 1 | 2012 | 754 | 0.060 |
Why?
| | Catecholamines | 1 | 1986 | 98 | 0.060 |
Why?
| | Ethics, Medical | 2 | 1999 | 84 | 0.060 |
Why?
| | Patient Readmission | 1 | 1991 | 697 | 0.060 |
Why?
| | United States Government Agencies | 1 | 2005 | 5 | 0.060 |
Why?
| | Geography | 1 | 2006 | 200 | 0.060 |
Why?
| | Forms and Records Control | 1 | 2005 | 23 | 0.060 |
Why?
| | Health Maintenance Organizations | 2 | 2003 | 108 | 0.060 |
Why?
| | Prospective Studies | 5 | 2020 | 7604 | 0.060 |
Why?
| | Economic Competition | 1 | 2004 | 14 | 0.060 |
Why?
| | Paper | 1 | 2024 | 10 | 0.060 |
Why?
| | Alkaloids | 1 | 2004 | 30 | 0.060 |
Why?
| | Laboratory Personnel | 1 | 2024 | 4 | 0.060 |
Why?
| | Academies and Institutes | 1 | 2005 | 53 | 0.060 |
Why?
| | Animal Welfare | 1 | 2024 | 14 | 0.060 |
Why?
| | Anticonvulsants | 1 | 2006 | 217 | 0.050 |
Why?
| | Health Care Coalitions | 1 | 2004 | 10 | 0.050 |
Why?
| | Compassion Fatigue | 1 | 2024 | 31 | 0.050 |
Why?
| | Genetic Engineering | 1 | 2004 | 93 | 0.050 |
Why?
| | Cyproheptadine | 4 | 1987 | 7 | 0.050 |
Why?
| | Occupational Stress | 1 | 2024 | 42 | 0.050 |
Why?
| | Odds Ratio | 2 | 2020 | 1070 | 0.050 |
Why?
| | Mass Screening | 1 | 2012 | 1287 | 0.050 |
Why?
| | Patient Safety | 2 | 2019 | 314 | 0.050 |
Why?
| | United States Occupational Safety and Health Administration | 1 | 2003 | 7 | 0.050 |
Why?
| | Labor Unions | 1 | 2003 | 4 | 0.050 |
Why?
| | Electronic Health Records | 1 | 2011 | 1069 | 0.050 |
Why?
| | Planning Techniques | 1 | 2003 | 16 | 0.050 |
Why?
| | Emergency Service, Hospital | 2 | 2014 | 2069 | 0.050 |
Why?
| | Liability, Legal | 4 | 1995 | 44 | 0.050 |
Why?
| | Inservice Training | 2 | 2016 | 116 | 0.050 |
Why?
| | Japan | 1 | 2002 | 115 | 0.050 |
Why?
| | Polyvinyls | 1 | 2002 | 21 | 0.050 |
Why?
| | Awareness | 1 | 2003 | 103 | 0.050 |
Why?
| | Hydroxyzine | 1 | 2022 | 4 | 0.050 |
Why?
| | Databases as Topic | 1 | 2002 | 67 | 0.050 |
Why?
| | Polymethacrylic Acids | 1 | 2002 | 62 | 0.050 |
Why?
| | Administration, Cutaneous | 1 | 2002 | 129 | 0.050 |
Why?
| | Ethics, Business | 1 | 2001 | 2 | 0.050 |
Why?
| | Chromatography, High Pressure Liquid | 1 | 1984 | 597 | 0.050 |
Why?
| | Heart Diseases | 1 | 2005 | 346 | 0.050 |
Why?
| | Point-of-Care Systems | 1 | 2023 | 167 | 0.050 |
Why?
| | Telephone | 1 | 2002 | 173 | 0.050 |
Why?
| | Antibodies, Monoclonal | 1 | 1988 | 1430 | 0.050 |
Why?
| | Patents as Topic | 1 | 2021 | 1 | 0.040 |
Why?
| | Feedback | 1 | 2002 | 173 | 0.040 |
Why?
| | Varenicline | 1 | 2021 | 25 | 0.040 |
Why?
| | Feasibility Studies | 1 | 2025 | 956 | 0.040 |
Why?
| | Hand Hygiene | 1 | 2020 | 9 | 0.040 |
Why?
| | Radiologists | 1 | 2020 | 51 | 0.040 |
Why?
| | Aged, 80 and over | 1 | 2012 | 7635 | 0.040 |
Why?
| | Journalism, Medical | 1 | 2000 | 6 | 0.040 |
Why?
| | Perception | 1 | 2003 | 359 | 0.040 |
Why?
| | Conservation of Natural Resources | 1 | 2002 | 122 | 0.040 |
Why?
| | Labor, Obstetric | 1 | 2000 | 61 | 0.040 |
Why?
| | Dentistry | 1 | 2020 | 10 | 0.040 |
Why?
| | Freedom | 1 | 2000 | 14 | 0.040 |
Why?
| | Computer Graphics | 1 | 2020 | 42 | 0.040 |
Why?
| | Music | 1 | 2000 | 43 | 0.040 |
Why?
| | Masks | 1 | 2020 | 63 | 0.040 |
Why?
| | Social Values | 1 | 2000 | 36 | 0.040 |
Why?
| | International Agencies | 1 | 2020 | 35 | 0.040 |
Why?
| | Hypoglycemic Agents | 1 | 2009 | 1291 | 0.040 |
Why?
| | Death | 1 | 2000 | 119 | 0.040 |
Why?
| | Social Perception | 1 | 2001 | 108 | 0.040 |
Why?
| | Breast Neoplasms | 1 | 2012 | 2253 | 0.040 |
Why?
| | Cost of Illness | 1 | 2022 | 308 | 0.040 |
Why?
| | Public Health Surveillance | 1 | 2020 | 82 | 0.040 |
Why?
| | Ethics | 2 | 1996 | 10 | 0.040 |
Why?
| | Pilot Projects | 1 | 2024 | 1710 | 0.040 |
Why?
| | Electrocardiography | 1 | 2022 | 629 | 0.040 |
Why?
| | Foundations | 1 | 2018 | 28 | 0.040 |
Why?
| | Insulin | 1 | 2009 | 2409 | 0.040 |
Why?
| | Contracts | 1 | 1998 | 12 | 0.040 |
Why?
| | Social Behavior | 1 | 2001 | 287 | 0.040 |
Why?
| | Employment | 1 | 2020 | 178 | 0.040 |
Why?
| | Fiji | 1 | 2017 | 3 | 0.030 |
Why?
| | Health Status Indicators | 1 | 1998 | 171 | 0.030 |
Why?
| | Technology Assessment, Biomedical | 1 | 1997 | 33 | 0.030 |
Why?
| | Forecasting | 1 | 2018 | 389 | 0.030 |
Why?
| | Sampling Studies | 1 | 1996 | 99 | 0.030 |
Why?
| | Capacity Building | 1 | 2016 | 63 | 0.030 |
Why?
| | Diffusion of Innovation | 1 | 1997 | 99 | 0.030 |
Why?
| | Animals, Newborn | 3 | 1987 | 844 | 0.030 |
Why?
| | CD-ROM | 1 | 1995 | 6 | 0.030 |
Why?
| | Medical Informatics Applications | 1 | 1995 | 7 | 0.030 |
Why?
| | Anti-Infective Agents, Local | 1 | 2016 | 40 | 0.030 |
Why?
| | Stress, Psychological | 1 | 2024 | 1100 | 0.030 |
Why?
| | Patient Discharge | 1 | 2002 | 897 | 0.030 |
Why?
| | Developed Countries | 1 | 1995 | 39 | 0.030 |
Why?
| | Models, Statistical | 1 | 2020 | 669 | 0.030 |
Why?
| | Regional Medical Programs | 1 | 1995 | 7 | 0.030 |
Why?
| | Child, Preschool | 1 | 2010 | 11074 | 0.030 |
Why?
| | Analysis of Variance | 1 | 1998 | 1316 | 0.030 |
Why?
| | Software | 1 | 2020 | 665 | 0.030 |
Why?
| | Air Pollution | 1 | 2018 | 316 | 0.030 |
Why?
| | Diabetes Mellitus, Type 2 | 1 | 2009 | 2531 | 0.030 |
Why?
| | Drugs, Investigational | 1 | 2015 | 33 | 0.030 |
Why?
| | Communication Barriers | 1 | 1996 | 104 | 0.030 |
Why?
| | DNA-Binding Proteins | 1 | 2022 | 1502 | 0.030 |
Why?
| | Influenza, Human | 1 | 2020 | 622 | 0.030 |
Why?
| | Poison Control Centers | 1 | 1995 | 90 | 0.030 |
Why?
| | Palliative Care | 1 | 2000 | 758 | 0.030 |
Why?
| | Education, Medical, Undergraduate | 1 | 1995 | 188 | 0.030 |
Why?
| | Drug Contamination | 1 | 2013 | 53 | 0.020 |
Why?
| | Drug Stability | 1 | 2013 | 167 | 0.020 |
Why?
| | Solubility | 1 | 2013 | 245 | 0.020 |
Why?
| | Family Practice | 1 | 1996 | 464 | 0.020 |
Why?
| | Hospital Bed Capacity, 300 to 499 | 1 | 1991 | 4 | 0.020 |
Why?
| | Precision Medicine | 1 | 2015 | 429 | 0.020 |
Why?
| | Confidence Intervals | 1 | 2012 | 329 | 0.020 |
Why?
| | Dementia | 1 | 2015 | 259 | 0.020 |
Why?
| | Dissent and Disputes | 1 | 2011 | 20 | 0.020 |
Why?
| | National Health Programs | 1 | 2010 | 23 | 0.020 |
Why?
| | Zambia | 1 | 2010 | 57 | 0.020 |
Why?
| | Observer Variation | 1 | 1991 | 343 | 0.020 |
Why?
| | Chronic Disease | 1 | 2016 | 1793 | 0.020 |
Why?
| | Referral and Consultation | 2 | 1995 | 786 | 0.020 |
Why?
| | Training Support | 1 | 2010 | 35 | 0.020 |
Why?
| | Midwifery | 1 | 2010 | 52 | 0.020 |
Why?
| | Geriatric Assessment | 1 | 1991 | 224 | 0.020 |
Why?
| | San Francisco | 3 | 1995 | 52 | 0.020 |
Why?
| | Endpoint Determination | 1 | 2009 | 77 | 0.020 |
Why?
| | beta-Endorphin | 1 | 1988 | 8 | 0.020 |
Why?
| | Obstetrics | 1 | 2010 | 163 | 0.020 |
Why?
| | Immunoglobulin Fab Fragments | 1 | 1988 | 59 | 0.020 |
Why?
| | Molecular Weight | 1 | 1988 | 335 | 0.020 |
Why?
| | Iodine Radioisotopes | 1 | 1988 | 145 | 0.020 |
Why?
| | Enkephalin, D-Penicillamine (2,5)- | 1 | 1987 | 1 | 0.020 |
Why?
| | Migraine Disorders | 1 | 2009 | 102 | 0.020 |
Why?
| | 3,4-Dichloro-N-methyl-N-(2-(1-pyrrolidinyl)-cyclohexyl)-benzeneacetamide, (trans)-Isomer | 1 | 1987 | 3 | 0.020 |
Why?
| | Receptors, Opioid, kappa | 1 | 1987 | 10 | 0.020 |
Why?
| | Endorphins | 1 | 1987 | 10 | 0.020 |
Why?
| | Aging | 3 | 1987 | 1864 | 0.020 |
Why?
| | Enkephalins | 1 | 1987 | 20 | 0.020 |
Why?
| | Dynorphins | 1 | 1987 | 9 | 0.020 |
Why?
| | Hydrazines | 1 | 1987 | 35 | 0.020 |
Why?
| | Pyrrolidines | 1 | 1987 | 79 | 0.020 |
Why?
| | p-Chloroamphetamine | 1 | 1987 | 1 | 0.020 |
Why?
| | 5,7-Dihydroxytryptamine | 1 | 1987 | 3 | 0.020 |
Why?
| | Receptors, Opioid, mu | 1 | 1987 | 74 | 0.020 |
Why?
| | Hydroxyindoleacetic Acid | 1 | 1987 | 26 | 0.020 |
Why?
| | Early Detection of Cancer | 1 | 2012 | 447 | 0.020 |
Why?
| | Bipolar Disorder | 1 | 2009 | 263 | 0.020 |
Why?
| | Reserpine | 1 | 1986 | 3 | 0.020 |
Why?
| | Sympatholytics | 1 | 1986 | 15 | 0.020 |
Why?
| | Haloperidol | 1 | 1986 | 34 | 0.020 |
Why?
| | Corticosterone | 1 | 1987 | 236 | 0.020 |
Why?
| | Norepinephrine | 1 | 1986 | 204 | 0.010 |
Why?
| | Hypothalamo-Hypophyseal System | 1 | 1987 | 197 | 0.010 |
Why?
| | Piperazines | 1 | 1987 | 350 | 0.010 |
Why?
| | Electrochemistry | 1 | 1984 | 78 | 0.010 |
Why?
| | Peptide Fragments | 1 | 1987 | 706 | 0.010 |
Why?
| | Dopamine | 1 | 1986 | 303 | 0.010 |
Why?
| | Clinical Competence | 1 | 2010 | 1118 | 0.010 |
Why?
| | Fetus | 1 | 1987 | 806 | 0.010 |
Why?
| | Reading | 1 | 2002 | 135 | 0.010 |
Why?
| | Alendronate | 1 | 2000 | 15 | 0.010 |
Why?
| | Pravastatin | 1 | 2000 | 41 | 0.010 |
Why?
| | Television | 1 | 2000 | 75 | 0.010 |
Why?
| | Outpatients | 2 | 1993 | 396 | 0.010 |
Why?
| | Anticholesteremic Agents | 1 | 2000 | 153 | 0.010 |
Why?
| | European Union | 1 | 1997 | 12 | 0.010 |
Why?
| | Aspirin | 1 | 2000 | 387 | 0.010 |
Why?
| | Clinical Trials, Phase IV as Topic | 1 | 1995 | 4 | 0.010 |
Why?
| | Fees, Medical | 1 | 1995 | 9 | 0.010 |
Why?
| | Physicians' Offices | 1 | 1995 | 16 | 0.010 |
Why?
| | Home Nursing | 1 | 1995 | 25 | 0.010 |
Why?
| | Hotlines | 1 | 1995 | 32 | 0.010 |
Why?
| | Hospital Charges | 1 | 1995 | 44 | 0.010 |
Why?
| | Propofol | 1 | 1995 | 73 | 0.010 |
Why?
| | Poisoning | 1 | 1995 | 120 | 0.010 |
Why?
| | Insurance, Health | 1 | 1995 | 283 | 0.010 |
Why?
| | Medication Errors | 1 | 1993 | 95 | 0.010 |
Why?
| | Frail Elderly | 1 | 1993 | 131 | 0.010 |
Why?
| | Hospitals, Community | 1 | 1992 | 52 | 0.010 |
Why?
| | Medical Staff, Hospital | 1 | 1992 | 83 | 0.010 |
Why?
| | Curriculum | 1 | 1995 | 992 | 0.000 |
Why?
| | Endocrine Glands | 1 | 1987 | 15 | 0.000 |
Why?
| | Narcotics | 1 | 1987 | 52 | 0.000 |
Why?
| | Alcoholic Beverages | 1 | 1987 | 28 | 0.000 |
Why?
| | Maternal-Fetal Exchange | 1 | 1987 | 165 | 0.000 |
Why?
| | Follow-Up Studies | 1 | 1995 | 5131 | 0.000 |
Why?
| | Cocaine | 1 | 1987 | 166 | 0.000 |
Why?
| | Marijuana Abuse | 1 | 1987 | 233 | 0.000 |
Why?
| | Child Development | 1 | 1987 | 475 | 0.000 |
Why?
| | Disease Models, Animal | 1 | 1987 | 4295 | 0.000 |
Why?
|
|
Bero's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors People in Profiles who have published with this person. _
Similar People People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
|